All In Biotech

Free tool

FAERS Monitor: Rasonque

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220910 or its brand name (Rasonque, Daraxonrasib). Reports on generic versions are filed under their own applications.

Reports

10

Serious

10

100% of reports

Hospitalization

6

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dehydration4
  • diarrhoea4
  • nausea4
  • vomiting4
  • rash2
  • stomatitis2
  • abdominal pain upper1
  • ageusia1
  • blood potassium abnormal1
  • blood pressure decreased1
  • cardiac disorder1
  • disease progression1
  • dysgeusia1
  • dyspnoea1
  • fatigue1

Reports by year received

View as table
YearReports
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood potassium abnormal1789.4122.9196
ageusia184.313.120
stomatitis269.420.175
dehydrationSignal463.129.5187
blood pressure decreased131.74.97
dysgeusia128.34.46
cardiac disorder122.53.55
vomitingSignal417.98.449
disease progression117.82.84
diarrhoeaSignal413.06.134
nauseaSignal410.65.027
abdominal pain upper110.21.62
rash29.72.88
dyspnoea13.70.60
fatigue12.70.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.